Long-Term Management of Stable Mechanical Mitral Valve Replacement
For a woman with a stable mechanical mitral valve replacement, lifelong anticoagulation with a vitamin K antagonist (VKA) targeting an INR of 3.0 is mandatory, combined with low-dose aspirin (75-100 mg daily) if bleeding risk is low. 1
Anticoagulation Strategy
The cornerstone of management is lifelong VKA therapy with a target INR of 3.0 for all mechanical mitral valve replacements 1, 2. This higher target (compared to INR 2.5 for mechanical aortic valves) reflects the greater thrombotic risk in the mitral position due to lower flow velocities and larger surface area.
Key Anticoagulation Points:
- VKA (warfarin) is the only approved anticoagulant - Direct oral anticoagulants (DOACs) including dabigatran are absolutely contraindicated in mechanical valves 1, 2
- INR self-monitoring is recommended when appropriate training and quality control are available 2
- Add aspirin 75-100 mg daily if bleeding risk is low, as dual therapy may provide additional thromboembolic protection 1
Surveillance and Monitoring
Clinical Follow-Up:
- Regular INR monitoring to maintain therapeutic range (2.5-3.5 for mitral position)
- Annual clinical evaluation at minimum, with more frequent visits if symptoms develop
- Echocardiography should be performed if there are new symptoms, signs of valve dysfunction, or suspected thrombosis 1
Warning Signs Requiring Urgent Evaluation:
- New or worsening dyspnea, particularly if sudden onset
- Embolic events (stroke, peripheral embolism)
- Signs of hemolysis (unexplained anemia, dark urine)
- Subtherapeutic INR with new cardiac symptoms
Management of Anticoagulation Interruptions
For minor procedures (dental extractions, cataract surgery) where bleeding is easily controlled, continue VKA with therapeutic INR rather than bridging 1. This approach minimizes both thrombotic and bleeding risks.
For major procedures requiring anticoagulation interruption:
- Bridge with therapeutic-dose unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) 2
- The mitral position carries higher thrombotic risk than aortic, making bridging more critical
Critical Pitfalls to Avoid
- Never use DOACs - This is an absolute contraindication with documented harm 1
- Never accept subtherapeutic anticoagulation - Mechanical mitral valve thrombosis is life-threatening and can occur rapidly with inadequate anticoagulation 3
- Don't assume stability means less vigilance - Even "stable" valves require lifelong monitoring as thrombosis can occur at any time with inadequate anticoagulation
- Avoid NSAIDs and other drugs that increase bleeding risk when on dual therapy (VKA + aspirin)
Special Considerations for Women of Reproductive Age
If pregnancy is being considered, this requires intensive multidisciplinary planning before conception 4. The management becomes significantly more complex as warfarin is teratogenic in the first trimester, yet alternatives carry higher maternal thrombotic risk. This should involve cardiology, maternal-fetal medicine, and hematology consultation well in advance.
Long-Term Prognosis
Mechanical mitral valves provide excellent durability without structural deterioration 5, 6. Recent data show mechanical valves are associated with lower long-term mortality and dramatically lower reoperation rates compared to bioprosthetic valves (66% risk reduction for reoperation) 6, 7, though at the cost of 20-21% higher bleeding and stroke risk 6. The 10-year survival with mechanical mitral valves approaches 70-75% in contemporary series 5, 7.
Patient-specific factors (coronary artery disease, peripheral artery disease, smaller valve size) are more predictive of adverse outcomes than valve type itself 5, emphasizing the importance of managing comorbidities aggressively.